We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Doxycycline on Matrix Metalloproteinase Expression and Activity in the Abdominal Aneurysm

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00538967
First Posted: October 3, 2007
Last Update Posted: October 3, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Leiden University Medical Center
  Purpose
The matrix metalloproteinase-9 (MMP-9) is considered to play a central role in abdominal aortic aneurysm (AAA) initiation. Doxycycline has direct MMP-9 inhibiting properties in vitro, and it effectively suppresses AAA development in rodents. Observed inhibition of AAA progression, and contradictory findings in human studies evaluating the effect of doxycycline therapy on aortic wall MMP-9 suggest that the effects of doxycycline extend beyond MMP-9 inhibition, and that the effect may be dose dependent.

Condition Intervention Phase
Aortic Aneurysm, Abdominal Drug: doxycycline Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Basic Science
Official Title: The Effect of Doxycycline on Matrix Metalloproteinase Expression and Activity in the Abdominal Aneurysm

Resource links provided by NLM:


Further study details as provided by Leiden University Medical Center:

Primary Outcome Measures:
  • Collagenase mRNA and protein expression [ Time Frame: 2 weeks ]

Enrollment: 60
Study Start Date: May 2002
Study Completion Date: August 2005
Arms Assigned Interventions
No Intervention: 1
Active Comparator: 2
doxycycline 50 mg/day
Drug: doxycycline
2 weeks once daily
Active Comparator: 3
doxycycline 100 mg
Drug: doxycycline
2 weeks once daily
Active Comparator: 4
doxycycline 300 mg
Drug: doxycycline
2 weeks once daily

Detailed Description:
In this clinical trial, we evaluated the effect of two weeks of low (50 mg/day), medium (100 mg/day) or high dose (300 mg/day) doxycycline versus no medication in patients undergoing elective AAA repair. The effect of doxycycline treatment on MMP and cysteine proteases, and their respective inhibitors was evaluated in an integrative approach.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Elective open aneurysm repair

Exclusion Criteria:

  • Severe kidney and liver dysfunction
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00538967


Locations
Netherlands
Leiden University Medical Center
Leiden, Netherlands, 2300RC
Sponsors and Collaborators
Leiden University Medical Center
Investigators
Principal Investigator: Jan HN Lindeman, MD, PhD Leiden University Medical Center
  More Information

ClinicalTrials.gov Identifier: NCT00538967     History of Changes
Other Study ID Numbers: P00.146
First Submitted: October 2, 2007
First Posted: October 3, 2007
Last Update Posted: October 3, 2007
Last Verified: October 2007

Keywords provided by Leiden University Medical Center:
Collagenases
MMP
Cathepsins
Doxycycline
Aneurysm

Additional relevant MeSH terms:
Aneurysm
Aortic Aneurysm
Aortic Aneurysm, Abdominal
Vascular Diseases
Cardiovascular Diseases
Aortic Diseases
Doxycycline
Anti-Bacterial Agents
Anti-Infective Agents
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents